StockData
Lyell Immunopharma, Inc. logo

Lyell Immunopharma, Inc. (LYEL) stock

LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$13.67−0.98 (-6.69%)

Close on Nov 17, 2026Market cap $334.99MP/E –Yield –

Earnings

Lyell Immunopharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 11, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$3.00K
-80.0% on a year earlier
EPS, Q3 FY2026
–
Latest guidance
Issued
Mar 11, 2025 · 1 item

Quarterly results

Revenue and earnings per share from each of Lyell Immunopharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 11, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 4, 2026after the close$3.00K-80.0%–Release
Q2 FY2026ended Jun 30, 2026Aug 6, 2026after the close$4.00K––Release
Q1 FY2026ended Mar 31, 2026May 6, 2026after the close$2.00K-71.4%–Release
Q4 FY2025ended Dec 31, 2025Mar 12, 2026after the close$6.00K-45.5%–Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025after the close$15.00K––Release
Q2 FY2025ended Jun 30, 2025Aug 12, 2025after the close–––Release
Q1 FY2025ended Mar 31, 2025May 13, 2025after the close$7.00K+133.3%–Release
Q4 FY2024ended Dec 31, 2024Mar 11, 2025after the close$11.00K-15.4%–Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close–––Release
Q2 FY2024ended Jun 30, 2024Aug 7, 2024after the close$13.00K-51.9%–Release
Q1 FY2024ended Mar 31, 2024May 6, 2024before the open$3.00K-97.0%–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Lyell Immunopharma guided for has been reported

Guidance history

Every forecast Lyell Immunopharma put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Mar 11, 2025net cash useFY2025$175.00M – $185.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Lyell Immunopharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. News
  3. Results
  4. Results
  5. Results
  6. Results
  7. Update
  8. Results
  9. Update
  10. Results
  11. Results
  12. News
  13. Results
  14. Update
  15. Update

See a number that looks wrong?